Cognition Therapeutics
13
0
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.7%
1 terminated/withdrawn out of 13 trials
90.9%
+4.4% vs industry average
0%
0 trials in Phase 3/4
50%
5 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Role: lead
Expanded Access Program for CT1812 (Zervimesine)
Role: lead
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Role: lead
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Role: lead
Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
Role: lead
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Role: lead
Effect of CT1812 Treatment on Brain Synaptic Density
Role: lead
Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects
Role: lead
Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers
Role: lead
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
Role: lead
Drug Interaction Study of CT1812 in Healthy Volunteers
Role: lead
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
Role: lead
Ascending Dose Study of CT1812 in Healthy Volunteers
Role: lead
All 13 trials loaded